Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
2.380
+0.030 (1.28%)
At close: Jul 17, 2026, 4:00 PM EDT
2.410
+0.030 (1.26%)
After-hours: Jul 17, 2026, 7:31 PM EDT
Veru Inc. Employees
Veru Inc. had 20 employees as of September 30, 2025. The number of employees decreased by 190 or -90.48% compared to the previous year.
Employees
20
Change (1Y)
-190
Growth (1Y)
-90.48%
Revenue / Employee
n/a
Profits / Employee
-$697,651
Market Cap
38.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 20 | -190 | -90.48% | 20 | 0 |
| Sep 30, 2024 | 210 | 21 | 11.11% | 210 | 0 |
| Sep 30, 2023 | 189 | -44 | -18.88% | 189 | 0 |
| Sep 30, 2022 | 233 | -19 | -7.54% | 233 | 0 |
| Sep 30, 2021 | 252 | -87 | -25.66% | 252 | 0 |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| PDS Biotechnology | 21 |
| RenovoRx | 17 |
| Lantern Pharma | 16 |
| CervoMed | 15 |
| Nutriband | 13 |
| Actuate Therapeutics | 12 |
| Hyperion DeFi | 9 |
VERU News
- 12 days ago - Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day - GlobeNewsWire
- 6 weeks ago - Veru pact with Novo ‘significant event,’ says Canaccord - TheFly
- 6 weeks ago - Veru announces clinical supply agreement with Novo Nordisk - TheFly
- 2 months ago - Veru price target lowered to $24 from $25 at Oppenheimer - TheFly
- 2 months ago - Veru Inc. Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Veru Inc. Earnings release: Q2 2026 - Filings
- 2 months ago - Veru Inc. Quarterly report: Q2 2026 - Filings
- 2 months ago - Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress - GlobeNewsWire